Literature DB >> 6965303

Regulation of Fc fragment-induced murine spleen cell proliferation.

E L Morgan, W O Weigle.   

Abstract

Murine splenic lymphocytes proliferate in response to supernatant material derived from Fc fragment-pulsed splenic adherent cells. The stimulatory supernatant results from the interaction of Fc fragments with adherent cells or adherent cell supernate. Isolation of the stimulatory material in the supernate by Sephadex chromatography revealed that the mitogenic component was a cleavage product of Fc with a mol wt of approximately 14,000. The spleen cell type responsible for the generation of mitogenic Fc subfragments appears to be a macrophage. Unstimulated macrophages release an active supernate without being exposed to Fc fragments. The supernate of unstimulated macrophages apparently contain an enzyme which is capable of cleaving Fc fragments into the 14,000-mol wt mitogenic molecules. The spleen cell population induced to proliferate in response to the adherent cell supernate is present in T-cell depleted and Sephadex G-10 filtered cell preparations. Depletion of cells bearing immunoglobulin on their surfaces results in a reduced proliferative response to the mitogenic supernatant material indicating that it is probably a B cell.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6965303      PMCID: PMC2185750          DOI: 10.1084/jem.151.1.1

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  Antigen-antibody complexes produced in chickens tolerant to bovine serum albumin.

Authors:  D D Eardley; C H Tempelis
Journal:  J Immunol       Date:  1975-09       Impact factor: 5.422

2.  Peptide inhibition of the Prausnitz-Küstner reaction.

Authors:  R N Hamburger
Journal:  Science       Date:  1975-08-01       Impact factor: 47.728

3.  Enhancement of the humoral response of T cell-depleted murine spleens by a factor derived from human monocytes in vitro.

Authors:  D D Wood; S L Gaul
Journal:  J Immunol       Date:  1974-09       Impact factor: 5.422

4.  Regulation of the immune response. X. Antigen-antibody complex inactivation of cells involved in adoptive transfer.

Authors:  N R Sinclair; R K Lees; S Abrahams; P L Chan; G Fagan; C R Stiller
Journal:  J Immunol       Date:  1974-11       Impact factor: 5.422

5.  Direct demonstration of lymphocyte--macrophage cooperation in the absence of physical contact between the two cell types.

Authors:  C E Calkins; E S Golub
Journal:  Cell Immunol       Date:  1972-12       Impact factor: 4.868

6.  Separation of mouse spleen cells by passage through columns of sephadex G-10.

Authors:  I A Ly; R I Mishell
Journal:  J Immunol Methods       Date:  1974-08       Impact factor: 2.303

Review 7.  Membrane immunoglobulins and antigen receptors on B and T lymphocytes.

Authors:  N L Warner
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

8.  Carrier-specific enhancement of the immune response using antigen-antibody complexes.

Authors:  G Terres; G S Habicht; R D Stoner
Journal:  J Immunol       Date:  1974-02       Impact factor: 5.422

9.  The requirement for macrophages in the in vitro immune response.

Authors:  K Shortman; J Palmer
Journal:  Cell Immunol       Date:  1971-10       Impact factor: 4.868

10.  Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s).

Authors:  I Gery; B H Waksman
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307

View more
  12 in total

1.  A receptor for monomeric IgG2b on rat macrophages.

Authors:  S Denham; R Barfoot; E Jackson
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

2.  Isolation and identification of a biologically active peptide derived from the CH3 domain of human IgG1.

Authors:  E L Morgan; T E Hugli; W O Weigle
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

3.  In vitro effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation.

Authors:  E de Vries; J P van der Weij; C J van der Veen; H C van Paassen; M J Jager; H P Sleeboom; O L Bijvoet; A Cats
Journal:  Immunology       Date:  1982-09       Impact factor: 7.397

4.  Suppressive B-cell factor (SBF) produced by FcR-bearing B cells; suppression of B, but not non-B-cell proliferation.

Authors:  T Suzuki; M Miyama-Inaba; T Masuda; H Uchino; A Murakami; H Tanaka
Journal:  Immunology       Date:  1983-09       Impact factor: 7.397

5.  Potentiation of specific human in vitro immune responses by the Fc portion of human immunoglobulin.

Authors:  E L Morgan; W O Weigle
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

6.  Enhancement of T lymphocyte functions by Fc fragments of immunoglobulins. I. Augmentation of allogeneic mixed lymphocyte culture reactions requires I-A- or I-B-subregion differences between effector and stimulator cell populations.

Authors:  E L Morgan; M L Thoman; W O Weigle
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

7.  Polyclonal activation of human B lymphocytes by Fc fragments. I. Characterization of the cellular requirements for Fc fragment-mediated polyclonal antibody secretion by human peripheral blood B lymphocytes.

Authors:  E L Morgan; W O Weigle
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

8.  Selective proteolysis of immunoglobulins by mouse macrophage elastase.

Authors:  M J Banda; E J Clark; Z Werb
Journal:  J Exp Med       Date:  1983-04-01       Impact factor: 14.307

9.  Regulation of the immune response. I. The potentiation of in vivo and in vitro immune responses by Fc fragments.

Authors:  E L Morgan; S M Walker; M L Thoman; W O Weigle
Journal:  J Exp Med       Date:  1980-07-01       Impact factor: 14.307

10.  Activation of Fc receptor-bearing lymphocytes by immune complexes. II. Killer lymphocytes mediate Fc ligand-induced lymphokine production.

Authors:  M E Neville; H W Lischner
Journal:  J Exp Med       Date:  1981-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.